When Margaret Washington was diagnosed with Type 2 diabetes, her doctor told her she'd need to make major lifestyle changes. But like millions of others, Margaret found diet and exercise alone weren't enough to get her blood sugar under control. Now, a new drug called retatrutide is offering hope to people like her.
Retatrutide is what's called a triple-action medication — it works on three different receptors in the body that control blood sugar, appetite, and energy use. Unlike older diabetes drugs that target just one or two of these pathways, retatrutide targets three: GIP, GLP-1, and glucagon receptors. That three-pronged attack appears to make a real difference.
In a Phase 3 clinical trial called TRANSCEND-T2D-1, researchers tested retatrutide on adults with Type 2 diabetes whose blood sugar wasn't controlled through diet and exercise alone. After 40 weeks, patients receiving retatrutide saw their long-term blood sugar marker (called HbA1c) drop by an average of 1.7% to 1.9%. Those receiving a placebo only dropped 0.8%.
The weight loss numbers were even more striking. Participants taking retatrutide lost between 11.5% and 15.3% of their body weight on average, compared to just 2.6% for those on placebo. That's more than five times the weight loss.
Dr. Harpreet S. Bajaj, one of the study's authors, said this triple-action approach could help patients who need more intensive treatment. "This new triple-action medication has the potential to improve health outcomes for some patients," Bajaj noted, "including greater weight loss, especially for those who may require more intensive treatment regimens to manage their Type 2 diabetes."
The most common side effects were stomach-related — nausea and diarrhea — but researchers described them as generally mild to moderate, and they tended to improve as patients continued the once-weekly injection.
Researchers caution that more work remains. Longer-term studies are already underway to confirm the drug's safety and effectiveness. But for the 462 million people worldwide living with Type 2 diabetes, retatrutide represents a promising new option — one that tackles the condition from three angles at once.
"We're not there yet, but this is a significant step forward," said one researcher involved in the trial. "For patients who have struggled with existing treatments, this could be a game-changer."